Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report) were up 4.9% during mid-day trading on Monday . The company traded as high as $2.40 and last traded at $2.36. Approximately 175,997 shares were traded during mid-day trading, a decline of 20% from the average daily volume of 220,970 shares. The stock had previously closed at $2.25.
Analysts Set New Price Targets
Separately, HC Wainwright cut shares of Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th.
Get Our Latest Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Stock Performance
The stock has a market capitalization of $166.47 million, a P/E ratio of -0.90 and a beta of 1.04. The company's fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $2.34.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of IKT. Soleus Capital Management L.P. bought a new position in Inhibikase Therapeutics in the 4th quarter valued at about $20,556,000. Fairmount Funds Management LLC acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $19,906,000. ADAR1 Capital Management LLC acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $16,585,000. Nantahala Capital Management LLC acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $7,118,000. Finally, Blackstone Inc. acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter worth approximately $6,730,000. 3.81% of the stock is owned by institutional investors.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Featured Articles
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
